Grant Award Summary The Naloxone Project received a $600,000 Project Grant from the Federal Office of Rural Health Policy under the Rural Healthcare Services Programs (CFDA 93.912) to implement the Colorado Change (Coalition for Harm Reduction, Access to Naloxone, and Grassroots Rural Engagement) Project from September 1, 2025 through August 31, 2026. This Rural Communities Opioid Response Program—Overdose Response initiative addresses the opioid crisis in Colorado's rural communities, where...
Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $709,085 Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year implementation trial extending through January 31, 2031, designed to facilitate in-hospital opioid treatment program (OTP) intakes among hospitalized patients with opioid use disorder (OUD) across four hospitals....
Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Tufts University School of Medicine a Project Grant of $652,766 (awarded May 1, 2026; completion February 28, 2031) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Extended-Release Opioid Use Disorder Treatment in Massachusetts (EXOUD-MASS) study. This research initiative addresses the critical gap between national opioid overdose death rates—nearly 85,000 annually as of June...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...
This $3,000,000 Project Grant award from the Executive Office of the President Office of the National Drug Control Policy (ONDCP) supports the Research and Data Analysis federal grant program (CFDA 95.007). The grant funds nine organizations to deliver community-level intervention initiatives to combat drug overdoses from September 1, 2021 to August 31, 2022. The University of Baltimore receives $3 million to oversee the grant, with specific services delivered through eight sub-awards. These...
This $1,600,000 Project Grant award from the U.S. Department of Justice's Bureau of Justice Assistance (BJA) under the Comprehensive Opioid, Stimulant, and Substance Use Program (CFDA 16.838) aims to reduce overdose fatalities and promote sustained recovery from substance use disorders among residents of Williamson County, Texas. Key project activities include: Securing residential withdrawal management treatment beds for uninsured/underinsured individuals with assessed medical needs, linking...
This federal Project Grant award of $459,045, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a study titled "The Cascade of Care for Patients with Opioid Use Disorder Identified Through a Large Public Health System." The study aims to modify the existing Opioid Use Disorder (OUD) Cascade of Care model to better reflect the changing landscape of real-world OUD treatment, enabling critical research...
The Altarum Institute, in partnership with Faces & Voices of Recovery and Change Matrix, was awarded a $2,500,000 Cooperative Agreement by the U.S. Department of Justice's Bureau of Justice Assistance (CFDA 16.838 Comprehensive Opioid, Stimulant, and other Substances Use Program) to serve as the Category 2A Training and Technical Assistance (TTA) Center for Access to Treatment, Peer Recovery, and other Recovery Support Services. The TTA Center will assist COSSUP grantees and the broader...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $431,750 to Rutgers, The State University of New Jersey to conduct research on informing national overdose prevention and treatment strategies for high-risk adolescents. The key objectives of this 2-year project are to: 1) estimate the prevalence of adolescent nonfatal drug overdose and identify high-risk demographic and clinical subgroups,...
TTC'S OVERDOSE TREATMENT ACCESS (OD-TA) PROJECT - TARZANA TREATMENT CENTERS, INC. (TTC) WILL EXPAND ACCESS TO OPIOID OVERDOSE (OO) EDUCATION AND NALOXONE DISTRIBUTION (OEND) IN LOS ANGELES COUNTY (LAC) THROUGH THE DEVELOPMENT AND IMPLEMENTATION OF TWO SCALABLE TRAINING OF TRAINERS (TOT) PROGRAMS: 1) OEND BEST PRACTICES FOR FQHCS, COMMUNITY CLINCS AND PHARMACIES TOT PROGRAM (OENDCCP); AND 2) OEND BEST PRACTICES FOR COLLEGE CAMPUSES TOT PROGRAM (OEND CC). THE OENDCCP WILL RECRUIT HEALTHCARE "CHAMPIONS" OR PROVIDERS (DOCTORS, PHYSICIAN ASSISTANTS, NURSE-PRACTITIONERS, NURSES, MEDICAL ASSISTANTS, COMMUNITY HEALTH WORKERS, ETC.) AND PHARMACISTS FOR A HALF-DAY, IN-PERSON TRAINING ON INNOVATIVE PRACTICES, POLICIES, PROCEDURES, AND MODELS OF CARE FOR PRESCRIBING/CO-PRESCRIBING AND OTHERWISE EXPANDING ACCESS TO NALOXONE IN COMMUNITIES WITH HIGH RATES OF OO DEATHS. PARTICULAR FOCUS WILL BE PLACED ON CULTURALLY INFORMED APPROACHES THAT ADDRESS SOCIAL STIGMA, MEDICAL MISTRUST, AND OTHER BARRIERS TO NALOXONE ACCESS IN THE PREDOMINANTLY RACIAL/ETHNIC MINORITY POPULATIONS SERVED BY THE TRAINEES. OEND "CHAMPIONS" WILL THEN RETURN TO THEIR SITE TO TRAIN OTHER STAFF AND BUILD SITE-SPECIFIC CAPACITY TO PROVIDE EFFECTIVE OEND SERVICES THAT ARE CULTURALLY RESPONSIVE TO THE POPULATION SERVED. AT LEAST TWO (2) TRAININGS WILL BE HELD EACH YEAR (1 DURING YEAR ONE) WITH 30-40 PROVIDERS EACH FOR A MINIMUM OF 270 OEND CHAMPIONS TRAINED DURING THE 5-YEAR PROJECT. THE OEND CC WILL RECRUIT "COLLEGE AMBASSADORS" OR STUDENT LEADERS AND CAMPUS HEALTH CENTER PERSONNEL FROM LOCAL COMMUNITY COLLEGES AND UNIVERSITIES THROUGHOUT LAC FOR A HALF-DAY, IN-PERSON TRAINING ON INNOVATIVE PRACTICES, POLICIES, PROCEDURES, AND MODELS OF ENGAGEMENT FOR INCREASING ACCESS TO OEND ON COLLEGE CAMPUSES. FOCUS WILL BE PLACED ON CULTURALLY INFORMED APPROACHES FOR HISPANIC-SERVING INSTITUTIONS (HSIS) WHERE THE SAME CULTURAL BARRIERS TO NALOXONE ACCESS MAY PREVAIL AS IN PREDOMINANTLY LATINX COMMUNITIES. AT LEAST TWO (2) TRAININGS WILL BE HELD EACH YEAR (1 DURING YEAR ONE) WITH APPROXIMATELY 25 TRAINEES EACH FOR A TOTAL OF 225 OEND COLLEGE AMBASSADORS OR TRAINERS TRAINED DURING THE 5-YEAR PROJECT. BETWEEN THE TWO TOT PROGRAMS, A TOTAL OF 495 UNDUPLICATED INDIVIDUALS WILL BE TRAINED AS TRAINERS WITH AWARD FUNDS. EACH OEND CHAMPION OR TRAINER COMPLETING THE TOT PROGRAM WILL COMMIT TO TRAINING A MINIMUM OF 5 PROVIDERS AT THEIR SITE FOR A TOTAL OF 150-200 INDIVIDUALS TRAINED IN YEAR 1 AND 300-400 TRAINED ANNUALLY IN YEARS 2-5 FOR A TOTAL OF 1,350-1,800 INDIVIDUALS TRAINED IN OEND BEST PRACTICES FOR FQHCS, COMMUNITY CLINICS, & PHARMACIES BY THE END OF YEAR 5. MEANWHILE, EACH OEND COLLEGE AMBASSADOR COMPLETING THE TOT PROGRAM WILL TRAIN A MINIMUM OF 5-10 STUDENTS/HEALTH CENTER STAFF AT THEIR CAMPUS FOR A TOTAL OF 125-250 INDIVIDUALS TRAINED IN YEAR 1 AND 250-500 TRAINED DURING YEARS 2-5 FOR A TOTAL OF 1,125-2,250 INDIVIDUALS TRAINED BY THE END OF YEAR 5. TTC'S TOT PROGRAMS WILL ADDRESS SERVICE GAPS IN LAC WHERE HIGHER RATES OF AREA POVERTY WERE ASSOCIATED WITH HIGHER OO DEATH RATES. THE SPECIFIC GOALS OF THE TOT PROGRAMS ARE TO: 1) INCREASE CAPACITY OF LOCAL FQHCS, COMMUNITY CLINICS, AND PHARMACIES TO DEVELOP EFFECTIVE OEND PROGRAMS, INCLUDING INNOVATIVE AND CULTURALLY RESPONSIVE PRACTICES, IN HIGH-NEED COMMUNITIES; AND 2) INCREASE CAPACITY OF LOCAL HIS COMMUNITY COLLEGES AND STATE UNIVERSITIES TO DEVELOP EFFECTIVE AND INNOVATIVE OEND PROGRAMS, INCLUDING CULTURALLY RESPONSIVE PRACTICES, AMONG DIVERSE STUDENT POPULATIONS. BY THE END OF YEAR 5, THE RATE OF ED VISITS AND HOSPITALIZATIONS DUE TO OO WILL BE REDUCED BY AT LEAST 25% FROM BASELINE (2022). ANNUALLY DURING YEARS 1-5, AT LEAST 533 NALOXONE NASAL SPRAY KITS WILL BE DISTRIBUTED TO OEND CHAMPIONS FOR DISTRIBUTION TO PATIENTS AT HIGHEST RISK FOR OO, AND APPROXIMATELY 5-10 PATIENTS WHO HAVE EXPERIENCED AN OO WILL BE LINKED TO OUD TREATMENT EACH YEAR THROUGH AN ENHANCEMENT OF LINKAGE TO TREATMENT PROTOCOLS WITH PARTICIPATING FQHCS AND COMMUNITY CLINICS.